Gilead Sciences, a cancer-drug maker, agreed Monday to pay about $11.9 billion to buy Kite Pharma, a move to expand its product lineup in cancer immunotherapies.
In the cash deal, expected to close in the fourth quarter, Gilead will pay Kite shareholders $180.00 per Kite share.
Kite develops drugs in cell therapy, which uses a patient’s own immune cells to fight cancer.
Axicabtagene ciloleucel, Kite’s most advanced therapy drug currently under review by the U.S. Food and Drug Administration, is expected to be the first to market as a treatment for refractory aggressive non-Hodgkin lymphoma, the company said.
“The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients,” Gilead CEO John Milligan said in a statement. “Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.”
By Roger Yu
Source: USA Today
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
